Introduction 26
The first bone morphogenetic protein (BMP) was discovered by Dr. Marshall Urist, an 27 orthopaedic surgeon in UCLA, in the 1960s. These proteins were shown to trigger the 28 formation of bone and cartilage from mesenchymal stem cells in culture [1] . Since then, more 29 than 22 members of the BMP family have been identified, along with a smaller set of plasma 30 membrane receptors that activate a well-defined canonical signalling pathway involving the 31 Smad1/5/8 proteins. Today, it is clear that BMP signalling extends beyond bone and cartilage 32 formation, and is involved in such diverse biological processes as stem cell and organ 33 formation, muscle development, iron metabolism, vascular biology and cancer. In addition, it 34 is increasingly appreciated that a counterbalance of BMP and TGFβ signalling exists in many 35 physiological processes and disease states. In 2010, we published a review in this journal 36 summarising, to the best of our ability, the "state of play" regarding BMP signalling. It is an 37 intramolecular disulphide bonds that form a ring, and a third cysteine pair which bonds 142 through the ring completing the knot. TGFβ family members have seven conserved cysteine 143 residues, whereas BMP antagonists have 6 cysteine residues. Other conserved structural 144 features of the TGFβ family members are that of the wrist and knuckle epitopes [48] . The 145 knuckle epitope is formed by four anti-parallel β-sheets and the wrist is formed by a four-turn 146 alpha-helix at the region of dimerization. Two BMP monomers form an antiparallel dimer, 147 covalently linked through a disulfide bond. Ternary co-crystal 3D structures of BMP-BMP- 148 receptor complexes show that type I receptors interact with the wrist motif and type II 149 receptors interact with the knuckle region [49] [50] [51] . The BMP antagonists Noggin and Chordin 150 have 4 additional amino acids, generating ten-membered rings. The disulphide bridges in the 151 cysteine rings ensure a strict structural conformation of the antagonists by ensuring correct 152 folding of the peptide, backbone stability and exposure of key hydrophobic residues [43, 48] . 153 Two co-crystal structures of BMP-BMP antagonist vividly demonstrate the similarities and 154 differences in antagonist binding. The first co-crystal, BMP-7 in complex with Noggin, 155 reveals a butterfly structure (Fig. 3a) . The structure also reveals that the Noggin dimer forms 156 a two-fold axis of symmetry with a head-to-head conformation rather than the overlapping Further, a recently detailed set of data demonstrates that the DAN family of protein 182 antagonists form highly stable non-covalent dimers [56] . The antagonists, Protein Related to 183 Dan or Cerberus (PRDC, also known as Gremlin2) and DAN, form non-covalent 184 homodimers that do not require the unpaired cysteine residue of the cystine knot [56] . PRDC 185 and DAN dimers are highly stable, as they did not dissociate after treatment with DTT, 186 heating to 100 o C, or incubation with 4M urea [56] . The crystal structure of PRDC/Gremlin2 187 has also been resolved, and it shows that PRDC forms a non-covalent head-to-tail growth 188 factor-like dimer with an extensive hydrogen bond network between monomers ( Fig. 3d , 189 [46]). Mutagenesis of PRDC identified residues belonging to the DAN domain on the convex 190 surface, rather than the N-terminus that are critical for BMP binding affinity. An N-terminal 191 latch mechanism for BMP binding was therefore proposed due to the observed flexibility and 192 potential for conformational sampling of the N-terminal domain that exposes the DAN 193 domain residues upon interaction with a BMP ligand [46] . 194 The diversity of structures already seen within the family of BMP antagonists provides 195 mechanistic and functional information that contributes to our understanding of the finely 196 tuned specificities and affinities for BMP antagonists to BMP ligands and, in turn, to BMP 197 signal transduction. The structures of many more cysteine knot domain containing proteins, 198 BMP antagonists and BMP co-complexes, remain to be resolved, and this information will Grem1, as well as other proteins such as the Endoglin CD105 co-receptor [60] . Another 215 example of antagonist cooperation was recently demonstrated for the BMP modulators BMP 216 endothelial cell precursor derived regulator (BMPER) and twisted gastrulation (Twsg1).
217
BMPER is the human ortholog of crossveinless-2 found in Drosophila, and was shown to 218 activate BMP-4 at low concentrations, but inhibit BMP-4 signalling at higher concentrations, 219 in an endocytic trap-and-sink mechanism in mouse endothelial cells [59] . BMPER has also 220 been implicated in endothelial cell biology and angiogenesis, where the BMP antagonist 221 Twsg1, but not Noggin or Chordin, was found to increase HUVEC sprouting in vitro and 222 endothelial cell growth in a Matrigel plug assay in vivo [61, 62] . Interestingly, these Twsg1- MicroRNA regulation in BMP signalling 228 There has been a dramatic increase in the identification of miRNAs that regulate BMP 229 signalling ( Table 1) . Among these is miR-21, which has been detected in skin epidermis, 230 specifically keratinocytes, and is highly expressed in hair follicle tumours [63] . miR-21 is a 231 downstream target of BMP-4 in mouse keratinocytes, and treatment of these cells with BMP-232 4 dramatically reduced miR-21 levels, an effect that was reversed by overexpression of the 233 BMP antagonist Noggin [63] . Furthermore, miR-21 regulates two groups of BMP-4 target 234 genes in keratinocytes that are involved in tumour suppression and cell differentiation. In 235 addition, BMP-4 downregulates the miR302~367 cluster in a Smad1/5 dependent manner in 236 human primary pulmonary artery smooth muscle cells (PASMCs) [64] . BMPRII was found 237 to be the target of miR302, and therefore inhibition of miR-302 by BMP-4 increases BMP-4 238 signalling by stabilizing the BMPRII transcript [64] . Also, miR-656 represses the expression 239 of BMPR1A in U87 glioma cells and inhibits glioma tumorigenesis [65] . Similarly, BMP-2 240 mediated glioma growth was inhibited by lentiviral miR-656 expression in mice suggesting a 241 tumour suppressor role for miR-656 [65] . MiR-130a also targets BMP type I receptors, in this 242 case ALK2 in liver cells [66] . The levels of miR-130a are increased by iron deficiency, which 243 leads to a decrease in BMP-6/Smad1/5 signalling. As a result, levels of hepcidin, the main 244 iron regulatory hormone in the body, are reduced, leading to increased iron availability in the 245 circulation [66]. miR-22 has been identified as a master regulator of BMP-7/6 in the kidney 246 [67] , where BMP-7/6 have been proposed to act as anti-fibrotic BMPs in chronic diseases of 247 the kidney, lung and other tissues (e.g. [68]). miR-22 deletion reduces the severity of kidney 248 injury induced by unilateral ureteral obstruction (UUO), with higher levels of both BMP-7 249 and BMP-6 evident in miR-22-/-kidneys post-UUO [67] . A concomitant increase in 250 BMPRIb levels and pSmad1/5/8 phosphorylation was also observed in miR-22-/-kidneys, 251 with miR-22 binding sites identified in the 3' untranslated region of BMP-7, 6 and BMPRIb 252 [67] . Interestingly, miR-22 is itself a transcriptional target of BMP-7/6 signalling, with 253 several BMP response elements identified in the miR-22 promoter. This study identifies miR-254 22 as a key regulator of kidney fibrosis, and suggests that an auto-feedback loop likely exists 255 between BMP-7/6 and miR-22 in the normal kidney and regulates kidney physiology (Table   256 1).
257
As well as inhibiting the expression of BMPs and their membrane receptors, some miRs have were increased, while pSmad3 (TGFβ1 target) was reduced ( Fig. 4, [152] ).
510
TGFβ1 is the primary pro-fibrotic cytokine that mediates tissue fibrosis, and strategies aimed and their antagonists, as well as with TGFβ. Identifying these interactions will increase the 582 opportunities for pharmacological intervention to modify BMP/BMP antagonist signalling, 583 similar to the Grem1 targeting approach developed in pulmonary artery hypertension. We 584 eagerly anticipate future developments in this field, and emerging BMP-targeting therapies 585 that will improve disease treatment and patient outcomes. whereas TGFβ is well established as a primary fibrotic driver in many tissues. BMP-7 616 signalling is potentiated by the binding of Kielin/Chordin-like protein-1 (KCP-1), which 617 facilitates BMP-7 binding to its cognate receptors. In contrast, KCP-1 binds to TGFβ and 618 prevents it binding to its receptors, thus inhibiting its signalling. BMP-7 and TGFβ signalling 619 are also counter balanced in cancer stem cell differentiation and the regulation of muscle 620 mass (see text for details). Acknowledgements 634 We apologise to colleagues whose work was not cited in this review due to space limitations. 
